Research programme: anticancer therapeutics - NantCancerStemCellAlternative Names: Small molecule therapies - NantCancerStemCell
Latest Information Update: 23 Jul 2015
At a glance
- Originator NANTCANCERSTEMCELL
- Class Small molecules; Stem cell therapies
- Mechanism of Action Hypoxia-inducible factor-1 alpha inhibitors; Proto oncogene protein c-myc inhibitors; Tumour suppressor protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer